# 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

> **NCT07310355** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Chengdu StarRay Therapeutics Co., Ltd** · enrollment: 49 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** 68Ga-PSMA-0057
- **DRUG:** 177Lu-PSMA-0057

## Key facts

- **NCT ID:** NCT07310355
- **Lead sponsor:** Chengdu StarRay Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2028-06-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07310355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07310355, "68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07310355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*